How This Works
Tirzepatide is a novel dual agonist that simultaneously activates GLP‑1 (glucagon‑like peptide‑1) and GIP (glucose‑dependent insulinotropic polypeptide) receptors. This dual mechanism enhances glucose‑dependent insulin secretion while suppressing glucagon release, slowing gastric emptying, and promoting satiety through central appetite regulation. The added GIP activity appears to synergistically amplify metabolic effects beyond GLP‑1 alone, contributing to superior weight reduction observed in clinical trials. Its ~5‑day half‑life enables convenient once‑weekly administration.
Potential Benefits & Side Effects
Observations from clinical trials.
Glycemic control: Significant HbA1c reductions in type 2 diabetes trials.
Weight reduction: Clinical trials report substantial body‑weight loss (up to ~11 kg more than GLP‑1 RA comparators over 26 weeks at higher doses).
Cardiovascular markers: Improvements in lipid profiles and blood pressure observed in some studies.
Common side effects: Gastrointestinal (nausea, diarrhea, vomiting, constipation) — typically mild‑to‑moderate and dose‑dependent; gradual titration reduces incidence.
Injection‑site reactions: Occasional mild redness or irritation at subcutaneous injection sites.
Dosage Guide: https://help.purepeptide.st/en/articles/13207129-tirzepatide-10mg-vial-dosage-protocol
Disclaimer:
The information provided in this article is for educational and informational purposes only and is not intended as medical advice. These statements have not been evaluated by the FDA or Health Canada. Peptides and other compounds discussed are intended for research purposes only and are not approved for human consumption unless prescribed by a licensed medical professional. Always consult your healthcare provider before starting any new protocol, supplement, or treatment.